A 510(k) premarket notification is the submission most new moderate-risk medical devices use to reach the U.S. market. Rather than proving a device is safe and effective from scratch, a 510(k) asks the FDA to find the device substantially equivalent to a device already legally marketed in the United States — a “predicate” device.
Named for the section of the Federal Food, Drug, and Cosmetic Act that created it (Section 510(k)), the pathway is administered by FDA’s Center for Devices and Radiological Health (CDRH) and is by volume the most common way a device reaches U.S. market clearance.
For a research administrator or technology-transfer office, the 510(k) determines whether a device invention can move toward commercialization through a comparatively fast, well-defined regulatory route, or whether it needs the far larger evidentiary burden of a Premarket Approval (PMA). Understanding which pathway applies — and how it interacts with pre-market clinical testing under an Investigational Device Exemption (IDE) — is foundational to planning a device study’s timeline and budget.
Device classification: the gate that determines which pathway applies
Before any submission question arises, FDA classifies every medical device into one of three risk-based classes under 21 CFR Part 860, and that classification is what determines whether a 510(k), a PMA, or no premarket submission at all is required:
- Class I — lowest risk, subject to general controls only (e.g., manufacturing and labeling requirements). Most Class I devices are exempt from premarket submission entirely.
- Class II — moderate risk, where general controls alone are insufficient but special controls (such as performance standards or specific labeling) provide reasonable assurance of safety and effectiveness. Most Class II devices require a 510(k).
- Class III — highest risk, typically devices that support or sustain life, are implanted, or present an unreasonable risk of illness or injury. General and special controls are not considered sufficient, so these devices require a Premarket Approval (PMA) rather than a 510(k).
A device’s classification is usually determined by the classification already assigned to its generic device type (its FDA product code) under 21 CFR Parts 862-892. A sponsor developing a genuinely novel device with no existing classification and no predicate can use the De Novo pathway to request that FDA classify it into Class I or II directly, rather than defaulting to the Class III/PMA route simply because no predicate exists.
The substantial equivalence standard
Substantial equivalence, not independent proof of safety and effectiveness, is the legal standard a 510(k) has to meet. Per FDA’s own guidance, a new device is substantially equivalent to a predicate if it:
- has the same intended use as the predicate, and
- has the same technological characteristics as the predicate, or
- has different technological characteristics, but the submitter demonstrates the device is as safe and effective as the predicate and does not raise different questions of safety and effectiveness.
The predicate device is typically a device already legally marketed in the U.S. — either cleared through a prior 510(k), classified through De Novo, or in limited cases a pre-1976 “grandfathered” device. If FDA determines the device is not substantially equivalent (an “NSE” decision), it is automatically placed into Class III and generally requires a PMA, a De Novo request, or a reclassification petition to move forward.
510(k) vs. PMA
The two pathways differ in what they ask a sponsor to prove and how long that takes:
- 510(k) — applies to most Class II (and some Class I) devices. The sponsor demonstrates substantial equivalence to a predicate; clinical data is often not required unless the device raises new questions of safety or effectiveness. FDA’s review goal is measured in weeks to a few months.
- PMA — applies to Class III devices. The sponsor must independently demonstrate reasonable assurance of safety and effectiveness, typically supported by clinical investigation data, in a submission FDA reviews to a substantially higher evidentiary standard and a substantially longer statutory review timeline than a 510(k).
510(k) vs. IDE: premarket clearance vs. pre-market clinical testing
A 510(k) and an Investigational Device Exemption (IDE) answer different questions at different points in a device’s lifecycle, and research administrators frequently need both concepts distinguished clearly for sponsors and investigators:
- An IDE (21 CFR Part 812) is the mechanism that permits an investigational device — one not yet cleared or approved for the use being studied — to be used in a clinical study to collect the safety and effectiveness data needed to support a future 510(k) or PMA submission. Significant-risk device studies require FDA approval of an IDE application before enrollment; nonsignificant-risk studies follow abbreviated IDE requirements overseen primarily by the reviewing IRB.
- A 510(k) is the premarket submission itself — the request for FDA to clear the device for commercial distribution, typically filed once the sponsor has whatever supporting data (bench, clinical, or comparative) is needed to demonstrate substantial equivalence to a predicate.
In practice, a device study intended to support a future 510(k) will often still need IDE approval (or an IDE exemption determination) before human subjects can be enrolled, because the device is investigational — not yet cleared for the use under study — at the time the trial runs.
Types of 510(k) submissions
FDA recognizes three 510(k) submission types, distinguished mainly by how much the new device changes relative to its predicate:
- Traditional 510(k) — the standard pathway, used for most new-to-market devices seeking clearance against a predicate.
- Special 510(k) — for a device modification made by the same manufacturer to its own already-cleared device, where the modification doesn’t affect the intended use or fundamental scientific technology and can be supported by the manufacturer’s own design-control documentation.
- Abbreviated 510(k) — relies on FDA guidance documents, special controls, and/or recognized consensus standards to streamline the submission, rather than a direct predicate comparison on every point.
Typical review timeline
Review timelines are set as MDUFA (Medical Device User Fee Amendments) performance goals, measured in “FDA days” — calendar days excluding time the submission spends on hold awaiting an Additional Information (AI) response from the submitter:
- Traditional and Abbreviated 510(k) — FDA’s MDUFA goal is a decision within 90 FDA days of receipt.
- Special 510(k) — FDA’s goal is a decision within 30 FDA days of receipt, reflecting the narrower scope of review.
- If FDA has not reached a decision within 100 FDA days (10 days past the 90-day goal), it issues a “Missed MDUFA Communication” explaining the outstanding review issues.
These are FDA’s internal performance goals, not statutory deadlines, and actual clearance timelines depend heavily on submission quality — additional information (AI) requests routinely add weeks or months to the total elapsed calendar time, even though the review clock itself pauses while the sponsor responds.
Frequently asked questions
Does every medical device need a 510(k)?
No. Most Class I devices are exempt from premarket submission entirely, and some Class II devices are also exempt by regulation. A 510(k) is required for devices whose classification regulation calls for one — check the device’s specific product code and classification regulation rather than assuming by class alone.
What is a predicate device?
A predicate is a device already legally marketed in the U.S. that the new device is compared against to establish substantial equivalence — most often a previously 510(k)-cleared device, though a device classified via De Novo or a small set of pre-1976 devices can also serve as predicates.
Can a 510(k) be cleared without clinical data?
Often, yes — many 510(k)s rely on bench testing, performance data, and a direct comparison to the predicate’s technological characteristics. Clinical data is required when it’s necessary to resolve questions about safety or effectiveness that non-clinical testing can’t answer, particularly where the new device’s technological characteristics differ from the predicate’s. Many 510(k) submissions for devices with a meaningful use-error risk also include human factors and usability engineering data, separate from the clinical or bench evidence used to establish substantial equivalence.
What happens if FDA finds a device “not substantially equivalent”?
An NSE decision automatically places the device into Class III by operation of law. The sponsor’s options are then a PMA, a De Novo request (if no predicate exists but the device is otherwise low-to-moderate risk), or a reclassification petition.
Is a 510(k) the same as FDA “approval”?
No — a 510(k) results in FDA clearance, not approval. “Approved” is reserved for PMA devices (and NDA/BLA drugs and biologics); 510(k)-cleared devices are described as cleared, reflecting the substantial-equivalence standard rather than an independent safety-and-effectiveness finding.
Related CASRAI resources
- Investigational Device — the IDE regulatory status a device holds during pre-market clinical study.
- FDA (Food and Drug Administration)
- Humanitarian Use Device (HUD) — a distinct, narrower pathway for devices treating rare conditions.
- Clinical Trial Phases
- What Is a Clinical Trial? The NIH Definition Explained
